Nickel-2,3,7,8,12,13,17,18-octaacetic acid-5,10,15,20-tetra-[3-carboranyl-methoxyphenyl]-porphyrin octamethylester (NiTCP) was given in a Cremophor EL, a polyethoxylated castor oil, and propylene glycol emulsion to BALB/c mice bearing transplanted s.c. KHJJ mammary carcinomas. A total dose of 244 microg NiTCP/gram body weight (gbw) (54 microg B/gbw) was given in 6 i.p. injections over a 32 hr period. Observations of behavior and changes in body weight and chemical and hematological blood tests indicated little or no toxicity from NiTCP over a period of 6-90 hr after injections. Boron concentrations near tumor margins were 160-180 microg B/g at 41-90 hr after the last injection. Tumor:normal brain boron concentration ratios reached approx. 10:1 and tumor:blood ratios reached approx. 250:1 after 4 days. There was no evidence of thrombocytopenia or other potentially important toxicities. Our findings place NiTCP among the leading candidates for pre-clinical experiments aimed toward improvement upon the compounds being tested for boron neutron-capture therapy of glioblastoma multiforme.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/(SICI)1097-0215(19960927)68:1<114::AID-IJC20>3.0.CO;2-A | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Targeting Brain Drug Delivery with Macromolecules Through Receptor-Mediated Transcytosis.
Pharmaceutics
January 2025
Key Laboratory of Molecular Biophysics, Institute of Biophysics, School of Health Sciences & Biomedical Engineering, Hebei University of Technology, Tianjin 300401, China.
Brain diseases pose significant treatment challenges due to the restrictive nature of the blood-brain barrier (BBB). Recent advances in targeting macromolecules offer promising avenues for overcoming these obstacles through receptor-mediated transcytosis (RMT). We summarize the current progress in targeting brain drug delivery with macromolecules for brain diseases.
View Article and Find Full Text PDFHeterogeneous head phantom for validating treatment planning system in boron neutron capture therapy.
Appl Radiat Isot
January 2025
Institute of Nuclear Engineering and Science, National Tsing Hua University, 101, Sec. 2, Kuang-Fu Road, Hsinchu, 30013, Taiwan; Nuclear Science and Technology Development Center, National Tsing Hua University, 101, Sec. 2, Kuang-Fu Road, Hsinchu, 30013, Taiwan. Electronic address:
In clinical boron neutron capture therapy (BNCT), the distribution of dose to a heterogeneous medium that is predicted by a treatment planning system (TPS) should be experimentally validated. A head phantom specifically developed for this purpose is described and demonstrated herein. The cylindrical phantom exhibits distinct regions made from four materials (polymethyl methacrylate, calcium phosphate, air, and boric acid) to approximate a head structure with explicitly defined skin, skull, and brain tissue with a cavity and tumor within.
View Article and Find Full Text PDFExpression rate of LAT1 in high-grade parotid gland carcinoma and potential of BNCT as a treatment option for recurrent parotid gland carcinoma.
Appl Radiat Isot
January 2025
Department of Otolaryngology Head and Neck Surgery, Osaka Medical and Pharmaceutical University, Takatsuki, Japan; BNCT Joint Clinical Institute, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Purpose: Boron neutron capture therapy (BNCT) perform as a treatment option for locally advanced or recurrent unresectable head and neck cancers since June 2020 in Japan. The effect of BNCT on parotid carcinoma, which presents a variety of histologic types, remains unclear. The object of this study was to investigate the antitumor efficacy of BNCT against parotid gland carcinoma by focusing on LAT1, which is involved in the uptake of L-BPA, the boron compound used in BNCT.
View Article and Find Full Text PDFA 77-year-old man was referred to our department because of macrohematuria, oliguria, and a serum creatinine level of 2.47 mg/dL during boron neutron capture therapy (BNCT) for oropharyngeal cancer. At baseline, his creatinine level had been 0.
View Article and Find Full Text PDFTranscriptome analysis of human oral squamous cancer SAS cells as an early response after boron neutron capture therapy.
Appl Radiat Isot
January 2025
Department of Molecular and Genomic Biomedicine, Nagasaki University Graduate School of Biomedical Sciences, 852-8523, Nagasaki, Japan; Central Radioisotope Division, National Cancer Center Research Institute, 104-0045, Tokyo, Japan; Division of BNCT, EPOC, National Cancer Center, Tokyo, Japan; Division of Chemotherapy and Clinical Cancer Research, National Cancer Center Research Institute, 104-0045, Tokyo, Japan. Electronic address:
Boron neutron capture therapy (BNCT) is based on nuclear reactions between thermal neutron and boron-10 preferentially distributed in the cancer cells. B-boronophenylalanine (BPA) is the approved drug for treatment of oral cancers for BNCT. However, the predictive biomarkers to evaluate therapeutic efficacy and side-effects have not been clarified yet.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!